ArticleHepatology international2013
The risk factors and diagnosis of cholangiocarcinoma.
Article in Hepatology international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Smoking, alcohol consumption, and the risk of extrahepatic cholangiocarcinoma: a meta-analysis.World journal of gastroenterology · 2013Pooled it
- Choledocholithiasis as a risk factor for cholangiocarcinoma: a nationwide retrospective cohort study.BMC gastroenterology · 2025Article
- Clinical significance of chromodomain helicase/ATPase DNA binding protein 1-like and human mutL homolog 1 gene expression in cholangiocarcinoma.Oncology letters · 2018Article
- Rare progression of cholangiocarcinoma: distal femoral metastasis.BMJ case reports · 2017Article
- Opisthorchiasis and cholangiocarcinoma in Southeast Asia: an unresolved problem.International journal of general medicine · 2017Review
- The multidisciplinary team meeting in the UK from the patients' perspective: comments and observations from cholangiocarcinoma patients and their families.International journal of general medicine · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholangiocarcinoma (CC) is a generally fatal malignancy of the biliary tree. Its incidence is increasing worldwide. Unfortunately, the diagnosis of CC frequently occurs late in the course of the disease, which contributes to the high mortality rate. Securing the diagnosis can prove difficult and may require a combination of imaging modalities, serum markers, and tissue sampling. Even with current best practice accurate diagnosis and staging is often elusive. We review current trends in the epidemiology of CC, current best practice in its diagnosis, and some of the emerging technologies and systems that may lead to improved diagnosis, staging, and, perhaps, outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.